Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))
- (2023): Rizzi A+, Asian Pac J Allergy Immunol Oct, Online ahead of print [REVIEW]
- (2022): Modi B+, Indian J Tuberc 69(4), 470-475 (56 cases)
Adverse reactions attributed to entire drug class 'Antimycobacterial (including antitubercular)'
Please login to view adverse reactions.
Alanine aminotransferase (ALT) increased
- (2024): Chen X+, J Clin Pharmacol Mar, Online ahead of print
- (2024): Quiroz-Aldave JE+, Expert Rev Endocrinol Metab Jan, Online ahead of print17% [REVIEW]
Metabolic syndrome (includes metabolic disorder)
- (2023): Lim J+, Open Forum Infect Dis Aug (e-Collection) (association)
Gastrointestinal disorder / discomfort
- (2018): Fei CM+, Malays J Med Sci 25(5), 1035% [REVIEW]
- (2020): Gezahegn LK+, PLoS One 15(11), e024134614%
Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)
- (2025): Chen R+, J Gastrointestin Liver Dis 34(1), 55-63 (pharmacogenomics)
- (2025): Cheng J+, Int J Clin Pharm Feb, Online ahead of print [REVIEW] (pharmacogenomics)
- (2025): de Los Santos-Fernández RL+, Br J Clin Pharmacol 91(6), 1660-1674 [REVIEW] (pharmacogenomics)
- (2025): Zhang S+, Infect Drug Resist 18, 2065-2078 [REVIEW]
- (2024): He Q+, Br J Clin Pharmacol Oct, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
- (2023): Akkahadsee P+, Sci Rep 13(1), 19880 [REVIEW]
- (2022): Jaramillo-Valverde L+, Mol Genet Genomic Med Jun, Online ahead of print (pharmacogenomics)
- (2022): Jaramillo-Valverde L+, Int J Mol Sci 23 (19), 11028 (pharmacogenomics)
- (2021): Becker MW+, World J Gastrointest Pharmacol Ther 12(3), 40-55 [REVIEW]
- (2021): Chanhom N+, Heliyon 7(4), e06852
- (2021): Huang YS+, J Chin Med Assoc Oct, Online ahead of print25%
- (2021): Jiang F+, Liver Int Apr, Online ahead of print5%
- (2021): Khiewkhern S+, Stud Health Technol Inform 281, 784-7886%
- (2021): Nataprawira HM+, Am J Case Rep 22, e930828 (6 cases)
- (2021): Zhu J+, J Clin Pharm Ther May, Online ahead of print
- (2020): Kumar PS+, EJIFCC 31(3), 242-247 (1 case / female)
- (2020): Radhika S+, Curr Drug Saf Jun, Online ahead of print14%
- (2020): Xu N+, Eur J Hosp Pharm Sep, Online ahead of print4%
- (2020): Yang M+, Pharmacol Res Perspect 8(6), e00696 [REVIEW]
- (2020): Zeleke A+, BMC Res Notes 13(1), 220%
Thrombocytopenia / platelets decreased
- (2023): Kaur A+, Indian J Tuberc 70(4), 489-496 [REVIEW]
Adverse effects / adverse reactions
- (2021): Trubnikov A+, Int J Environ Res Public Health 18(8) [REVIEW]
